Jennison Associates LLC Boosts Position in DBV TECHNOLOGIE/S (DBVT)
Jennison Associates LLC boosted its stake in shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) by 1.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,731,291 shares of the company’s stock after buying an additional 23,559 shares during the quarter. Jennison Associates LLC’s holdings in DBV TECHNOLOGIE/S were worth $38,885,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new stake in DBV TECHNOLOGIE/S during the second quarter valued at about $285,000. Exane Asset Management lifted its holdings in DBV TECHNOLOGIE/S by 17.9% during the second quarter. Exane Asset Management now owns 50,000 shares of the company’s stock valued at $964,000 after purchasing an additional 7,600 shares during the last quarter. First Midwest Bank Trust Division lifted its holdings in DBV TECHNOLOGIE/S by 36.7% during the second quarter. First Midwest Bank Trust Division now owns 136,986 shares of the company’s stock valued at $2,642,000 after purchasing an additional 36,798 shares during the last quarter. Millennium Management LLC lifted its holdings in DBV TECHNOLOGIE/S by 842.6% during the first quarter. Millennium Management LLC now owns 133,256 shares of the company’s stock valued at $3,074,000 after purchasing an additional 119,119 shares during the last quarter. Finally, BlackRock Inc. lifted its holdings in DBV TECHNOLOGIE/S by 4.7% during the second quarter. BlackRock Inc. now owns 309,520 shares of the company’s stock valued at $5,970,000 after purchasing an additional 14,032 shares during the last quarter. Institutional investors own 42.92% of the company’s stock.
Several equities research analysts have commented on the stock. BidaskClub raised shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a report on Friday, November 9th. Zacks Investment Research raised shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a report on Friday, November 16th. ValuEngine raised shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Finally, Bank of America dropped their price objective on shares of DBV TECHNOLOGIE/S from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $33.67.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/11/22/jennison-associates-llc-boosts-position-in-dbv-technologie-s-dbvt.html.
DBV TECHNOLOGIE/S Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Further Reading: Stop Order Uses For Individual Investors
Want to see what other hedge funds are holding DBVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DBV TECHNOLOGIE/S (NASDAQ:DBVT).
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.